Table 2 |
|||||||||
| Top 20 protein-protein interactions from occurrence ranking | |||||||||
| Proteini | Proteinj | Protein-protein interactioni-j | |||||||
| Symbol | Occurrence | Name | Symbol | Occurrence | Name |
Occurrence Oij |
Z-score | Z-rank | Average rank |
| MDM2 | 466 | Mouse double minute 2 homolog | TP53 | 1097 | Tumor protein p53 | 130 | 86.0 | 3355 | 2999.8 |
| TP53 | 1097 | Tumor protein p53 | UBC | 1899 | Ubiquitin C | 64 | 18.4 | 30486 | 16565.3 |
| HBA2 | 68 | Hemoglobin, alpha 2 | HBB | 76 | Hemoglobin, beta | 59 | 395.5 | 76 | 1360.3 |
| CBL | 414 | Cas-Br-M ecotro- pic sequence | EGFR | 626 | Epidermal growth factor receptor | 46 | 42.6 | 11054 | 6849.3 |
| CBL | 414 | Cas-Br-M ecotro- pic sequence | GRB2 | 916 | Growth factor receptor bound 2 | 44 | 33.2 | 15615 | 9129.8 |
| FANCA | 217 | Fanconi anemia, complementation A | FANCG | 143 | Fanconi anemia, complementation G | 43 | 117.3 | 1808 | 2226.3 |
| EGFR | 626 | Epidermal growth factor receptor | UBC | 1899 | Ubiquitin C | 41 | 15.8 | 34796 | 18720.3 |
| BRCA2 | 199 | Breast cancer 2, early onset | RAD51 | 171 | DNA repair protein RAD51 homolog 1 | 40 | 104.4 | 2288 | 2466.3 |
| HIF1A | 207 | Hypoxia inducible factor 1, alpha | VHL | 351 | von Hippel-Lindau tumor suppressor | 39 | 69.2 | 5071 | 3857.8 |
| HRAS | 164 | Ha-Ras1 proto-oncoprotein | RAF1 | 281 | Proto-oncogene c-RAF | 38 | 84.8 | 3444 | 3044.3 |
| SNAP25 | 131 | Synaptosomal-associated protein, 25kDa | STX1A | 183 | Syntaxin 1A | 37 | 114.7 | 1920 | 2282.3 |
| MAX | 145 | MYC associated factor X | MYC | 382 | Proto-oncogene c-Myc | 36 | 73.4 | 4568 | 3606.3 |
| BARD1 | 109 | BRCA1 assoc. RING domain 1 | BRCA1 | 448 | Breast cancer 1, early onset | 35 | 75.9 | 4279 | 3461.8 |
| GRB2 | 916 | Growth factor receptor bound 2 | SHC1 | 317 | SHC transforming protein 1 | 35 | 30.1 | 17593 | 10118.8 |
| CDH1 | 167 | Cadherin 1, type 1 | CTNNB1 | 470 | Catenin, beta 1 | 34 | 57.8 | 6876 | 4760.3 |
| E2F1 | 168 | E2F transcription factor 1 | RB1 | 385 | Retinoblastoma 1 | 34 | 64.0 | 5853 | 4248.8 |
| GRB2 | 916 | Growth factor receptor bound 2 | SOS1 | 125 | Son of sevenless homolog 1 | 32 | 44.9 | 10232 | 6438.3 |
| CCNA2 | 109 | Cyclin A2 | CDK2 | 286 | Cyclin-dependent kinase 2 | 31 | 84.3 | 3485 | 3064.8 |
| EGF | 76 | Epidermal growth factor | EGFR | 626 | Epidermal growth factor receptor | 31 | 68.2 | 5211 | 3927.8 |
| NFKBIA | 231 | Nucl. factor of kappa light chain gene enhancer in B-cells | RELA | 314 | V-rel reticulo-endotheliosis viral oncogene homolog A | 30 | 53.1 | 7932 | 5288.3 |
Top 20-ranked protein-protein interactions (PPIs), as identified by the number of times they were observed in the aggregated data set. The quantities and calculations are annotated as in Table 1, except that the data were sorted in decreasing order of PPI occurrence Oij. The proteins involved in these interactions are easily recognizable, and this partly reflects an underlying study-bias of focusing research efforts on a smaller set of high-interest proteins.
Yu et al. BMC Bioinformatics 2012 13:79 doi:10.1186/1471-2105-13-79